This Open House Webinar is intended for those interested in leaning more about the Postgraduate Certificate in Psychedelic Harm Reduction and Integration. The Fluence Certificate program is designed to teach clinicians to engage in Psychedelic Harm Reduction and Integration in clinical settings. The Certificate is not a license or authorization to practice therapy in itself, but a course of study covering key elements and experiences, providing exposure to mentors and leaders in the field, and introducing participants to a peer group for ongoing professional support and development.

The webinar features Fluence leadership and representatives of our teaching and mentoring faculty, as well as a recent program graduate.

 All registrants who complete this program will receive an application fee waiver code, $100 Value.

This webinar was recorded live/online on September 28th, 2022.

Find out more about this certificate program by clicking here.

Instructors

Psychedelic Integration Therapy Certificate Program Director

Alexander Camargo, Psy.D

Dr. Alex Camargo is a psychologist based in New York City and maintains a private practice in Manhattan. His work is heavily influenced by psychoanalytic and attachment theories where he works with clients to address anxiety, depression, life transitions and spiritual crises. In addition, he provides psychedelic harm reduction and integration, helping clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience. He has also been employed to be a study therapist on a clinical trial investigating the impact of psilocybin on the treatment of body dysmorphic disorder at New York Psychiatric Institute. Dr. Camargo’s clinical training focused on providing mental health services in low-fee clinics and hospitals to traditionally underserved communities the Bronx, Brooklyn, and Nassau County.

Lead Trainer

Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.